EP3568125A1 - Système support nanostructuré de principe actif - Google Patents

Système support nanostructuré de principe actif

Info

Publication number
EP3568125A1
EP3568125A1 EP18703472.3A EP18703472A EP3568125A1 EP 3568125 A1 EP3568125 A1 EP 3568125A1 EP 18703472 A EP18703472 A EP 18703472A EP 3568125 A1 EP3568125 A1 EP 3568125A1
Authority
EP
European Patent Office
Prior art keywords
carrier system
nanostructured
polymer
complexing
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18703472.3A
Other languages
German (de)
English (en)
Inventor
Anja TRÄGER
Anne-Kristin Trützschler
Tanja Bus
Ulrich Sigmar Schubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Friedrich Schiller Universtaet Jena FSU
Original Assignee
Friedrich Schiller Universtaet Jena FSU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friedrich Schiller Universtaet Jena FSU filed Critical Friedrich Schiller Universtaet Jena FSU
Publication of EP3568125A1 publication Critical patent/EP3568125A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)

Definitions

  • the invention relates to a nanostructured drug carrier system, in particular for reducing cytotoxic properties due to transport, for interacting with cell membranes during transport of hydrophilic components and, associated therewith, for generating early endosomal leakage of the interaction complex from the carrier system.
  • the mediation of the nucleic acids can be subdivided into the following areas:
  • nucleic acids in a hydrophobic polymeric system.
  • WO 2015058111 A1 discloses a nanoparticle in which a hydrophobic active substance as well as nucleic acids, preferably siRNA, are enclosed by the interaction with hydrophobic and / or cationic-hydrophilic enveloping polymers. This formulation is used for a controlled release of the active ingredients and for the protection of the nucleic acids.
  • the disadvantage of this technical solution is that cationic hydrophobic substances and amphiphilic polymers are used.
  • the corona used may possibly lead by the use of polyethylene glycol to an immune response already on antibodies-consuming organisms.
  • the application as an anticarcinogenic therapeutic agent is intended and beneficial for a longer release of the active ingredient and yet the moderately cytotoxic polyethylenimine is used.
  • the structure of the system with more than 2 different types of polymers also makes it difficult to produce the nanoparticles.
  • micellar polymer nanoparticles with complexation of nucleic acids on the outer corona discloses the formulation of micellar polymer nanoparticles with complexation of nucleic acids on the outer corona.
  • a block having cationic charges undergoes electrostatic binding to the genetic material (Biswas, S., Deshpande, PP, Navarro, G .; Dodwadkar, NS, Torchilin, VP, lipid modified triblock PAMAM-based nanocarriers for siRNA Biomaterials 2013, 34 (4), 1289-1301 Rinkenauer, AC; Schallon, A., Guenther, U .; Wagner, M., Betthausen, E., Schubert, US; Schacher, FH, A Paradigm Change: Efficient Transfection of Human Leukemia Cells by Stimuli Responsive Multicompartment Micelles, ACS Nano 2013, 7 (11), 9621-9631 and EP 2 522 689 Al and WO 2012/156058 Al.)
  • micellar systems are dynamic systems, which below the critical micelle concentration would mean a dissolution of the system into individual polymer strands, which is not expected for nanoparticles. It would be just in the entry into organisms a micelle dissolution or restructuring to be expected before the target organ or tissue is reached.
  • the polymers used are also a triblock system, which represents an increased production and characterization effort.
  • the complexation of the nucleic acids on the outer corona leads to an increased risk of decomposition of the nucleic acid by nucleases despite complexation.
  • micellization by inclusion of nucleic acids in the inner hydrophilic core of nanocarriers are known.
  • the formulation method used here is an intensive mixing of the components used (Osawa, S. Osada, K., Hiki, S., Dirisala, A., Ishii, T., Kataoka, K., Polyplex Micelles with Double- Protective Compartments of Hydrophilic Shell and Thermoswitchable Palisade of Poly (oxazoline) -Based Block Copolymers for Promoted Gene Transfection, Biomacromolecules 2016, 17 (1), 354-361; Feng, G., Chen, H .; Li, J .; Huang Gupte, MJ; Liu, H .; Song, Y .; Ge, Z., Gene therapy for nucleus pulposus regeneration by heme oxy genesis- 1 plasmid DNA carried by mixed polyplex micelles with thermo-responsive heterogeneous coronas 2015, 52, 1-13).
  • micellar systems show the same disadvantages which have already been mentioned above. For the mentioned micellar tube systems, a combination and thus in the production of the use of multiple block copolymers is also necessary.
  • nucleic acids include nucleic acids, for example:
  • nucleic acid formulations in nanoparticulate carrier systems consisting of cationic-hydrophilic and hydrophobic components
  • a high transfection efficiency can be achieved.
  • polymeric enveloping substances, homopolymers and block copolymers with amphiphilic character, and lipids are used.
  • formulations with low cytotoxicity are used.
  • the particles thus produced show high transfection efficiencies, high stability or preferred solubilities of the polyplexes.
  • the multicomponent carrier systems are made using polyethylene glycol-lipid conjugates and block copolymers and thus are also affected by the growing number of antibody-carrying organisms.
  • WO 2015035974 A1 discloses, for example, a nanostructured carrier system which comprises at least one polymer and / or at least one lipid and at least one polymethine dye, wherein the at least one polymethine dye acts as a targeting unit for the targeted transport of the nanostructured carrier system into a target tissue.
  • the disadvantage of this solution is that in this case a specific targeting is the goal and thus there is no accelerated endosomal outlet or drug delivery.
  • a use without the coloring properties of polymethine dyes is also much more pleasant for the end user.
  • Another disadvantage is the limited interaction of polyethyleneimine with membranes.
  • protein dimers and lipoid structures could be shown as complexing agents for the nanoparticulate core.
  • the disadvantage of this technical solution is the use of 2b protein, which is a protein from a tomato plant-infecting virus.
  • the use of these virus proteins is always an irritability of the immune system.
  • the preparation of the shell polymer by the additional conjugation with cholesterol and the associated targeting or shielding effect also represents a further working step and thus leads to high production costs.
  • WO 2010142660 A1 discloses a pharmaceutically active formulation in the form of microparticles of defined size comprising siRNA, a highly hydrophobic biodegradable polymer and a cationic lipid which functions both as an amphipathic emulsifier and as a siRNA binding moiety, the siRNA and the cationic lipid are encapsulated in the microparticle.
  • microparticles can cause a difficult uptake in cell tissue. These are preferably taken up by immune cells and degraded, which should normally be prevented.
  • lipids in the Wording partly a complicated large-scale production with itself. The particles are therefore also intended for pulmonary uptake, that is to say the intake via the respiratory tract, and here too do not depend on a chronologically determined uptake.
  • the known carrier systems for the transport of nucleic acids show in their entirety good transfection properties.
  • Another disadvantage is that there is often no interaction with the genetic material prior to micelle or particle formation.
  • the preparation processes for the carrier systems according to the prior art have the disadvantage that the preparation takes place by means of mixing in solution, the micelle formation by means of mixing in solution or dropwise addition in solution and twice the emulsion process (hydrophilic / hydrophobic / hydrophilic) are used, so that no inclusion process with prior complexation of the drug and subsequent nanoprecipitation of two solutions is possible.
  • polymers and polymer-lipid derivatives known from the prior art have one or more hydrophobic subsections and one or more hydrophilic subsections, so that these polymers or derivatives require a more elaborate preparation in order to produce nanoscale carrier systems.
  • the object of the present invention is to provide a nanostructured active substance carrier system which avoids the above-mentioned disadvantages of the prior art and in particular allows a reduction of cytotoxic properties due to the formulation via the transport route.
  • the nanostructured drug delivery system to be provided will allow interactions with cell membranes during the transport of hydrophilic components and, associated therewith, the generation of early endosomal leakage of the interaction complex from the carrier system.
  • composition which contains a nanostructured active ingredient carrier system according to the invention and suitable auxiliaries and additives.
  • Nanoparticles are structures that are smaller than 1 ⁇ and can be composed of several molecules. They are generally characterized by a higher surface to volume ratio and thus offer a higher chemical reactivity. These nanoparticles can consist of polymers.
  • Polymers are characterized by the repetition of certain units (monomers), but may also consist of several different repeat units.
  • the monomers are covalently bonded together (polymerization) by the chemical reaction and form the so-called polymer backbone at the linking polymerisable unit.
  • the unconnected groups form the side chains where functional groups can be located. If these polymers have some hydrophobic properties, they can form nanoscale structures (eg nanoparticles, micelles, vesicles) in an aqueous environment.
  • shell polymer is meant one or more different polymers which are in layers or as a blend to form a random mixture of two or more polymers a hydrophobic nanostructured drug carrier system in which an interaction complex is included and / or incorporated.
  • reaction complex is meant a complex formed by electrostatic interaction of one or more hydrophilic agents and one or more complexing polymers.
  • Active ingredient describes at least one pharmaceutical active ingredient selected from the group consisting of low molecular weight substances, inhibitors, inducers or contrast agents, and in particular also of higher molecular weight substances, eg.
  • the hydrophilic agents potentially therapeutically useful nucleic acids (eg interferin RNA, short hairpin RNA, microRNA, plasmid DNA) and proteins (eg antibodies, interferons, cytokines).
  • pharmaceutically active substance is understood to mean any inorganic or organic molecule, substance or compound that has a pharmacological effect.
  • pharmaceutical active substance is defined herein by the term “medicament” and “medicament”. used synonymously.
  • the active pharmaceutical ingredients may be those which have little or no bioavailability without inclusion in a nanoparticle or a liposome or have little or no stability in vivo.
  • the essence of the invention is that a nanostructured drug delivery system in the form of a shell polymer enclosed, highly reactive nucleic acid polymer complex u.a. provided for gene transport.
  • This nanostructured drug carrier system in the form of a particle consists of a carrier shell, wherein the carrier shell at least one or more hydrophobic shell polymers, one or more charged complexing polymers and one or more hydrophilic active ingredients wherein the complexing polymer interacts with the drug.
  • the at least one shell polymer is selected from the group consisting of polyesters, poly (meth) acrylates, polystyrene derivatives, polyamides, polyurethanes, polyacrylonitriles, polytetrafluoroethylenes, silicones, polyethylene glycols, polyethylene oxides and polyoxazolines and their copolymers in various compositions, such as. Random, gradient, alternating, block, graft or star copolymers.
  • the at least one shell polymer is a biocompatible polymer.
  • the at least one shell polymer is particularly preferably a hydrophobic, biodegradable polymer, particularly preferably selected from the group consisting of PLGA, PLA, PCL, PGA, PEG or POX.
  • the “complexing polymer” represents one or more hydrophilic polymers, which are able by electrostatic interaction to be able to represent an interaction complex with one or more hydrophilic active ingredients.
  • the complexing polymer consists of linear, water-soluble, cationic polymers in a proportion of 0 to 70% secondary amine functionalities in the polymer backbone.
  • This at least one complexing polymer is selected from the group consisting of polypeptides, poly (meth) acrylates, polystyrene derivatives, polyamides, polyurethanes, polyacrylonitriles, polyethylene glycols, polyethylene oxides and polyoxazolines and their copolymers in various compositions, such as.
  • the invention expressly excludes the use of polyethyleneimine.
  • nanoparticle as part of the nanostructured drug carrier system takes place as follows:
  • this nanostructured drug carrier system allows a reduction in cytotoxic properties, interactions with cell membranes during transport of hydrophilic components, and thus the generation of early endosomal leakage of the interaction complex from the carrier system resulting in optimal drug release.
  • Another object of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising such a nanostructured drug carrier system and suitable auxiliaries and additives.
  • auxiliaries and additives means any pharmacologically acceptable and therapeutically meaningful substance which is not a pharmaceutical active substance but can be formulated together with the pharmaceutical active substance in the pharmaceutical composition in order to influence, in particular to, qualitative properties of the pharmaceutical composition improve.
  • the auxiliaries and / or additives do not develop any significant or at least no undesirable pharmacological effect with regard to the intended treatment.
  • auxiliaries and additives are, for example, pharmaceutically acceptable inorganic or organic acids, bases, salts and / or buffer substances.
  • inorganic acids are hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and phosphoric acid, with hydrochloric acid and sulfuric acid in particular being preferred.
  • suitable organic acids are malic acid, tartaric acid, maleic acid, succinic acid, acetic acid, formic acid and propionic acid and particularly preferably ascorbic acid, fumaric acid and citric acid.
  • suitable organic acids are malic acid, tartaric acid, maleic acid, succinic acid, acetic acid, formic acid and propionic acid and particularly preferably ascorbic acid, fumaric acid and citric acid.
  • pharmaceutically acceptable bases are alkali hydroxides, alkali metal carbonates and alkali ions, preferably sodium. Mixtures of these substances can be used in particular for adjusting and buffering the pH.
  • Preferred buffer substances are also PBS, HEPES, TRIS, MOPS and other physiologically acceptable buffer substances.
  • auxiliaries and additives are solvents or diluents, stabilizers, suspending agents,
  • Preservatives fillers, cryoprotectors, emulsion mediators and / or binders and other conventional auxiliaries and additives known in the art.
  • the choice of excipients and the amounts of them to be used will depend on the pharmaceutical active and the mode of administration.
  • a nanostructured active substance carrier system which forms the pharmaceutical composition with the suitable auxiliaries and additives, can be carried out, for example, by the double emulsion method known per se.
  • the nanostructured drug carrier system and the pharmaceutical composition comprising such a nanostructured drug carrier system and suitable auxiliaries and additives, represent a hitherto unique, multiple combinable therapeutic systems to transport a variety of substances, especially pharmaceutical agents (eg nucleic acids but also phydrophilic molecules) into a cell, wherein the combination with the interaction complex leads to an early endosomal leakage.
  • pharmaceutical agents eg nucleic acids but also phydrophilic molecules
  • the safe transport into the cell is realized by the coat protein and the interaction complex.
  • the result is a fast endosomal exit, which is ensured by the interaction of the interaction complex with the endosomal membrane. In this way it is possible to efficiently and rapidly introduce and release one or more drugs into cells.
  • FIG. 1 the molecular weights and polydispersities of the Boc-protected polymers determined by a) SEC (DmAc, 0.21% LiCl, PMMA calibration) and b) the degree of polymerization determined by means of SEC and ⁇ -NMR spectroscopy,
  • FIG. 2 the elution diagram of size exclusion chromatography of the Boc-protected polymers taken by means of refractive index detection
  • FIG. 3 the reaction scheme of the complexing polymer preparation according to exemplary embodiment 1,
  • FIG. 4 the reaction scheme of the cleavage reaction of the Boc group according to exemplary embodiment 2
  • FIG. 5 the 2-D HSQC-NMR of the cleavage reaction of the Boc group according to exemplary embodiment 2,
  • FIG. 6 the elution diagram of the size exclusion chromatography of the complexing polymers taken by means of
  • FIG. 7 the molecular weights and polydispersities of the Boc-protected polymers determined by a) AF4 by MALS detection, b) and c) by means of SEC (0.1% TFA, 0.1M NaCl Dextran calibration / c DmAc, 0.21% LiCl, PMMA calibration) and d)
  • the degree of polymerization is determined by means of AF4 and ⁇ -NMR spectroscopy.
  • the pKA value of the polymers is determined from the titration,
  • FIG. 8 the titration curves of the complexing polymers 2 to 7 in a diagram against the total volume of the titration used
  • FIG. 9 the superimposition of the ⁇ - ⁇ spectra A) copolymer of the complexing polymers with Boc group B)
  • Fig. IA the size of the particles produced directly after the preparation and removal of the solvent and after lyophilization and resuspension in ultrapure water
  • FIG. 1B the polydispersity of the particles produced directly after the preparation and removal of the solvent and after freeze-drying and resuspension in ultrapure water
  • Fig. HC the zeta potential of the particles produced directly after the preparation and removal of the solvent and after freeze-drying and resuspension in ultrapure water.
  • FIG. 12A the relative viability of L929 fibroblast cells, 24 h after the addition of interaction complexes,
  • FIG. 12B the relative viability of L929 fibroblast cells, 24 h after the addition of nanoparticles (B) in the corresponding concentrations,
  • FIG. 13 the time-dependent uptake of the interaction complexes PI to P6 in HEK cells
  • FIG. 14 the time-dependent uptake of P6 and siRNA encapsulated nanoparticles in HEK cells compared to PEI nanoparticles
  • FIG. 15 the transfection efficiency of the interaction polyplexes with GFP-coded pDNA in HEK cells under the influence of serum-reduced medium (OptiMEM) and serum-containing standard growth medium (RPMI).
  • OptiMEM serum-reduced medium
  • RPMI serum-containing standard growth medium
  • BocAEMA N-ieri-butyloxycarbonyl- (2-aminoethyl) methacrylates
  • BocMAEMA N-methyl-N-tert-butyloxycarbonyl- (2-aminoethyl) methacrylates
  • DMAEMA N-Dimethyl (2-aminoethyl) methacrylates
  • reaction solution is then heated with stirring in an oil bath preheated to 70 ° C. for 38 h.
  • the copolymer is precipitated twice from tetrahydrofuran in n-hexane and dried under reduced pressure.
  • Fig. 1 The analytical data are shown in Fig. 1, the size exclusion chromatography is shown in Fig. 2, and the synthetic scheme is shown in Fig. 4.
  • the teri-butyloxycarbonyl (Boc) protected polymers are deprotected in 1M methanolic hydrochloric acid for 16 h, the solvent is removed under reduced pressure, dissolved in deionized water and freeze-dried for 24 h.
  • the synthesis scheme is shown in Fig. 3, the 2-D NMR is shown in Fig.5, the size exclusion chromatography is shown in Fig. 6, the analytical data are shown in Fig.7, and the titration curves with pK A value are shown in Fig. 8 and the ⁇ -NMR comparison of deprotection methods is shown in Fig. 9.
  • Embodiment 2 is a diagrammatic representation of Embodiment 1:
  • the particles used are prepared, for example, by means of double emulsion. High-frequency ultrasound is used, which favors the formation of nanoscale particles with the aid of the surface-active substance polyvinyl alcohol (PVA).
  • PVA polyvinyl alcohol
  • hydrophobic shell polymers are for this purpose in ethyl acetate, a with
  • a final concentration of 0.3% PVA in ultrapure water is used.
  • the interaction complex is formed beforehand from the complexing polymer and the genetic material, here the siRNA, in ultrapure water. Subsequently, a first emulsion of interaction complex and shell polymer is formed, which is subsequently transferred to water and after reuse of high-frequency ultrasound, a second emulsion is formed.
  • the particles are incubated for up to 48 h at room temperature so that the organic solvent can evaporate.
  • the particles formed are washed by centrifugation and resuspension in ultrapure water, added with 5% sucrose and frozen (-80 ° C) to be lyophilized.
  • Nanoparticles of PLGA, polymethacrylates and siRNA are reproducibly produced with constant parameters.
  • Embodiment 5 is a diagrammatic representation of Embodiment 5:
  • cytotoxicity studies are carried out according to the ISO 10993-5 protocol with mouse fibroblast cells L929.
  • the cells are seeded in DMEM growth medium (Dulbecco's modified Eagle's medium) at a cell concentration of 10 4 cells per well in a 96-well plate and incubated for 24 h at 37 ° C and 5% CO 2 .
  • DMEM growth medium Dulbecco's modified Eagle's medium
  • the medium is changed with fresh medium mixed with the reagent AlamarBlue.
  • Embodiment 6 is a diagrammatic representation of Embodiment 6
  • HEK human embryonic kidney cells
  • Polyplexes with YOYO-labeled pDNA or nanoparticles with Nile red and complexing polymer are added to the HEK cells and incubated for up to 4 h at 37 ° C, 5% C0 2 .
  • Cellular uptake is assessed by flow cytometry. A total of 10,000 cells are measured and all living cells (FSC / SSC scattering) are counted with a positive signal (FL1).
  • HEK cells are sown in microscopy vessels with glass bottom and the microscopic image of the cells takes place 1 to 4 hours after addition of the samples. Furthermore, the cell nucleus is stained with Hoechst 33342, lysosomes with LysoTracker Red DND-99 or LysoTracker Green DND-26, cell membrane with CellMask Orange plasma membrane stain.
  • Embodiment 7 is a diagrammatic representation of Embodiment 7:
  • HEK cells or a stable GFP-CHO cell line are sown in 24-well plates with a cell concentration of 10 15 cells / mL.
  • the medium is changed either with serum-reduced medium (OptiMEM) or serum-containing growth medium (RPMI 1640).
  • OptiMEM serum-reduced medium
  • RPMI 1640 serum-containing growth medium
  • Polyplexes or nanoparticles are added to the cells (50 ⁇ per well) and incubated for 4 h at 37 ° C, 5% CO 2. Thereafter, the supernatant is removed and the cells are incubated in fresh growth medium for a further 24 h to 72 h.
  • the analysis of the transfection efficiency is carried out by means of flow cytometry. For this, the cells are trypsinized and stained with propidium iodide for a live-death determination.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un système support nanostructuré de principe actif, en particulier pour la réduction de propriétés cytotoxiques sur la base de l'utilisation d'un polymère d'enrobage et du transport qui en résulte, pour des interactions avec des membranes cellulaires pendant le transport de constituants hydrophiles et la génération qui y est reliée d'une évacuation endosomale précoce du complexe d'interaction hors du système support. La présente invention vise à fournir un système support nanostructuré de principe actif qui évite les inconvénients de l'état de la technique et qui permet en particulier une réduction de propriétés cytotoxiques sur la base de l'utilisation d'un polymère d'enrobage et du transport qui en résulte. À cet effet, un système support nanostructuré de principe actif sous forme d'une particule constituée par une enveloppe support est utilisé, l'enveloppe support comprenant au moins un ou plusieurs polymères d'enrobage hydrophobes, un ou plusieurs polymères de complexation chargés ainsi qu'un ou plusieurs principes actifs hydrophiles, le polymère de complexation interagissant avec le principe actif.
EP18703472.3A 2017-01-10 2018-01-10 Système support nanostructuré de principe actif Withdrawn EP3568125A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102017100317.7A DE102017100317A1 (de) 2017-01-10 2017-01-10 Nanostrukturiertes Trägersystem zum Gentransport
PCT/DE2018/100012 WO2018130247A1 (fr) 2017-01-10 2018-01-10 Système support nanostructuré de principe actif

Publications (1)

Publication Number Publication Date
EP3568125A1 true EP3568125A1 (fr) 2019-11-20

Family

ID=61167847

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18703472.3A Withdrawn EP3568125A1 (fr) 2017-01-10 2018-01-10 Système support nanostructuré de principe actif

Country Status (4)

Country Link
US (2) US11376336B2 (fr)
EP (1) EP3568125A1 (fr)
DE (1) DE102017100317A1 (fr)
WO (1) WO2018130247A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017100317A1 (de) * 2017-01-10 2018-07-12 Friedrich-Schiller-Universität Jena Nanostrukturiertes Trägersystem zum Gentransport
DE102020002360A1 (de) 2020-04-18 2021-10-21 Friedrich-Schiller-Universität Jena Nanopartikel enthaltend Komplexe aus Nukleinsäuren und kationischen Copolymeren, Verfahren zu deren Herstellung und deren Verwendung zum Gentransfer in Zellen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230908A1 (en) * 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
DE102007059752A1 (de) * 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
WO2010142660A2 (fr) 2009-06-09 2010-12-16 Novartis Ag Système d'administration de médicaments
EP2522689A1 (fr) 2011-05-13 2012-11-14 Universität Bayreuth Non-viral transfection systems
EP2848262B1 (fr) * 2013-09-12 2020-11-04 SmartDyeLivery GmbH Ciblage spécifique à des cellules par des systèmes porteurs nanostructurés
US10874621B2 (en) * 2013-10-17 2020-12-29 The Brigham And Women's Hospital, Inc. Cationic nanoparticles for co-delivery of nucleic acids and therapeutic agents
DE102017100317A1 (de) * 2017-01-10 2018-07-12 Friedrich-Schiller-Universität Jena Nanostrukturiertes Trägersystem zum Gentransport

Also Published As

Publication number Publication date
DE102017100317A1 (de) 2018-07-12
WO2018130247A1 (fr) 2018-07-19
US20220401577A1 (en) 2022-12-22
US11376336B2 (en) 2022-07-05
US20200061206A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
Prakash Jain et al. Self assembling polymers as polymersomes for drug delivery
DE60208237T2 (de) Wasserlösliche und stabilisierte, selbstorganisierende polyelektrolyte
Han et al. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo
CN105579584B (zh) 用于将rna引入细胞的组合物
DE69535540T9 (de) Zusammensetzung enthaltend nukleinsäuren und kationische polymere, zubereitung und verwendung
Chen et al. A pH-responsive cyclodextrin-based hybrid nanosystem as a nonviral vector for gene delivery
Liu et al. Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer
Huang et al. Improving the oral delivery efficiency of anticancer drugs by chitosan coated polycaprolactone-grafted hyaluronic acid nanoparticles
DE60202366T2 (de) Unimolekulare polymerische micelle, die einen ionisierbaren kern enthalten
Wang et al. Retracted Article: A multifunctional self-dissociative polyethyleneimine derivative coating polymer for enhancing the gene transfection efficiency of DNA/polyethyleneimine polyplexes in vitro and in vivo
EP1796649B1 (fr) Systeme de nanotransport a architecture dendritique
US20220401577A1 (en) Nanostructured active ingredient carrier system
Tariq et al. Lipodendriplexes: A promising nanocarrier for enhanced gene delivery with minimal cytotoxicity
Gou et al. Improving anticancer activity and reducing systemic toxicity of doxorubicin by self-assembled polymeric micelles
Skandrani et al. Lipid nanocapsules functionalized with polyethyleneimine for plasmid DNA and drug co-delivery and cell imaging
WO2019110067A1 (fr) Nanoparticule hybride
DE60014133T2 (de) Lipid zur Verwendung in einer Liposomzusammensetzung zur Abgabe eines Mittels an eine Zelle
Liu et al. Chitosan as a condensing agent induces high gene transfection efficiency and low cytotoxicity of liposome
DE60306769T2 (de) Triblockpolymere für arzneistoff- oder genzufuhr auf nanokugelbasis
DE102011114986A1 (de) Sprühsystem
EP2741783B1 (fr) Nanocomplexes polyanioniques pour applications thérapeutiques
EP3214178B1 (fr) Transporteur de génes à base de polymère polydixylitol osmotique à base de polyol et utilisation associée
Khan et al. Polymeric micelles
WO2002000162A2 (fr) Systeme d'administration de medicaments
WO2018166651A1 (fr) Particules polymères organiques contenant comme stabilisant de la poly(oxazoline) et utilisation de poly(oxazolines) pour la stabilisation de particules polymères organiques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190807

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TRUETZSCHLER, ANNE-KRISTIN

Inventor name: BUS, TANJA

Inventor name: SCHUBERT, ULRICH SIGMAR

Inventor name: TRAEGER, ANJA

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220802